| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | Prolonged-release tablet |
| Reference number | 3643 |
| Indication | Treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Rinvoq may be used as monotherapy or in combination with methotrexate |
| Company | AbbVie Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/01/2021 |
| NICE guidance | TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |